Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study | Leukemia
The effect of varying the buffer pHs to (a) 5.4, (b) 5.8, and (c) 6.2.... | Download Scientific Diagram
Effect of Ara-C, daunorubicin, mitoxantrone and etoposide on the... | Download Scientific Diagram
Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells | PNAS
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - Annals of Oncology
Fernand Bteich on X: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin).
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study | Haematologica
Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology
Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells | PNAS
Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu2+ Gradient Method | SpringerLink
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
PDF) Outcome of Standard Induction Therapy with Daunorubicin and Ara-C (3+7) in Acute Myeloid Leukemia | Akhil Biswas - Academia.edu
Acute myeloid leukaemia (AML) and cytarabine pharmacogenomics
Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry - ScienceDirect
Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | PLOS ONE
Primary AML cells and cell lines resistant to cytarabine, daunorubicin... | Download Scientific Diagram
Biomolecules | Free Full-Text | Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine
Secondary AML Treatment | VYXEOS® (daunorubicin and cytarabine)
MRC-AML11 protocol flow chart. DAT 3 10: daunorubicin 50 mg/m 2 slow... | Download Scientific Diagram
A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model - ScienceDirect
Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies | Leukemia
A Review of Liposomal Daunorubicin in the Treatment of Acute Leukemia - touchONCOLOGY
IJMS | Free Full-Text | Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia | Pharmacogenomics
